Onkologie. 2013:7(2):90-91
Quality of life of a patient treated with cabazitaxel for metastatic prostate cancer
- Onkologicko-chirurgické oddělení, FN u sv. Anny, Brno
- Léčba metastatického karcinomu prostaty má pouze paliativní charakter. Chemoterapie docetaxelem v I. linii a cabazitaxelem v II. linii
The treatment for metastatic prostate cancer is only of palliative nature. Chemotherapy with docetaxel in the first line and with cabazitaxel
in the second line of treatment for castration-resistant prostate cancer has a prolonged survival benefit. Oncological treatment
also significantly affects the quality of life that includes not only the sense of physical health and physical performance status, but also
mental well-being, social functioning, and family relationships.
Keywords: castration-resistant prostate cancer, quality of life, docetaxel, cabazitaxel
Published: May 1, 2013 Show citation
References
- Collette L, van Andel G, Bottomley A, Oosterhof GON, Albrecht W, de Reijke TM, Fossa DS. Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European organisation for research and treatment of cancer genitourinary group. 2004; 22(19): 3877-3885.
Go to original source... - Berthold DR, Pond GRP, Roessner M, de Wit R, Eiseberger, Tannock IF. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: Relationships between prostate-specific antigen, pain and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008; 14(9): 2763-2767. Go to original source...
Go to PubMed... - De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer (mCRPC) progresing after docetaxel treatment: a randomized open-label trial. Lancet 2010; 376(9747): 1147-1154. Go to original source... Go to PubMed...